J.P. Morgan analyst Cory Kasimov weighed in today with a few insights on Juno Therapeutics Inc (NASDAQ:JUNO), after hosting a call with JUNO’s CEO Hans Bishop and CFO Steve Harr, as part of J.P. Morgan’s 2015 Spring Biotech Conference Call Series.

“On CD19 CAR-Ts; while JCAR014 is no longer being developed for registrational purposes, it is still important on a number of levels. JUNO is using it as a “translational lab” that will help inform future iterations of CAR-T products – One of the key issues remaining to be solved with CAR-Ts in the heme (and other) spaces is persistence. Optimizing the chemotherapy pre-regimen, optimizing the cell composition, as well as the eventual shift to a fully human CAR should all help on this front.”, the analyst noted.

Furthermore, “On CAR-T in solid tumors; unlike in leukemia where there is a lot of tumor floating around which triggers CAR-T cell expansion, there are a lot less circulating tumor cells in the setting of solid tumors, so it will be important to optimize cell expansion (in addition to persistence) – JUNO also noted that they believe mesothelin is a difficult target due to its expression pattern.”

The analyst rates Juno Therapeutics Inc shares an Overweight, with a price target of $66, which represents a potential upside of 44% from where the stock is currently trading.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a total average return of 12.8% and a 65.0% success rate. Kasimov has a -12.2% average return when recommending JUNO, and is ranked #269 out of 3607 analysts.

JUNO Chart